Myasthenia Gravis & Neuromuscular Junction Disorders: Clinical Patient Journey

Myasthenia gravis (MG) is an autoimmune disorder in which antibodies disrupt communication between nerves and muscles, causing fluctuating weakness that worsens with activity and improves with rest. Early recognition and modern therapy dramatically improve outcomes.

At The Medical Group of New Jersey, our neuromuscular team provides expert diagnosis, medication management, and comprehensive support to help patients maintain strength, function, and independence.

Symptom Onset & Initial Evaluation

Myasthenia gravis (MG) is an autoimmune disorder that affects communication between nerves and muscles, causing weakness that worsens with activity and improves with rest.

Common early signs include:

• Drooping eyelids (ptosis) or double vision (diplopia)
• Difficulty chewing, swallowing, or speaking clearly
• Arm or leg weakness that increases with use
• Shortness of breath, especially after exertion

If you experience sudden breathing difficulty, seek emergency care immediately; this may indicate a myasthenic crisis, a life-threatening condition requiring urgent treatment.

During your first visit, your neurologist will:

• Perform a detailed neurological and strength examination
• Order antibody tests for acetylcholine receptor (AChR) and MuSK antibodies
• Conduct repetitive nerve stimulation or single-fiber EMG to confirm neuromuscular junction dysfunction
• Recommend a chest CT or MRI to evaluate the thymus gland for thymoma (a tumor often associated with MG)

Diagnosis & Subtype Classification

Myasthenia gravis can be classified based on antibody type and distribution of symptoms:

• AChR-positive MG: Most common form; responds well to standard therapies.
• MuSK-positive MG: Often affects facial, neck, and respiratory muscles; may need different medications.
• Seronegative MG: No detectable antibodies, but diagnosis confirmed by EMG findings.
• Ocular MG: Weakness limited to eye muscles, sometimes progressing to generalized MG.

Your neurologist will combine test results and symptom patterns to confirm the diagnosis and tailor a treatment plan.

Treatment & Ongoing Management

With modern therapies, most patients achieve significant improvement or remission.

Symptomatic Therapy:

• Pyridostigmine (Mestinon®): Improves nerve-to-muscle communication and relieves fatigue.

Immunosuppressive Therapy:

• Corticosteroids (prednisone) to reduce immune activity.
• Steroid-sparing agents such as azathioprine, mycophenolate mofetil, or cyclosporine for long-term control.
• Monoclonal antibody treatments (eculizumab, ravulizumab, or rituximab) for refractory cases.

Rapid-Acting Treatments (for crisis or severe symptoms):

• Intravenous immunoglobulin (IVIG) or plasmapheresis to quickly remove circulating antibodies.

Surgical Management:

• Thymectomy (removal of the thymus gland): Recommended for many patients, even without a thymoma, to improve long-term outcomes.

Rehabilitation & Supportive Care

Living with MG requires a careful balance between activity and rest.

• Physical therapy: Helps maintain endurance and prevent deconditioning.
• Speech and swallowing therapy: Assists patients with bulbar symptoms.
• Respiratory monitoring: Regular pulmonary function testing ensures early detection of respiratory decline.
• Lifestyle management:
• • Get adequate rest and avoid overheating.
  • Inform all healthcare providers about your diagnosis—some medications can worsen MG (e.g., certain antibiotics or beta-blockers).
  • Stay up to date on vaccinations to reduce infection-related flare-ups.

Prognosis & Long-Term Monitoring

With ongoing care, most people with MG lead normal, active lives. Regular follow-ups allow your neurologist to monitor response to therapy, adjust medications, and prevent complications.

The Medical Group of New Jersey provides comprehensive, multidisciplinary care, combining neurology, pulmonology, and rehabilitation services to support each patient’s strength, safety, and long-term well-being.